| Similar Articles |
|---|
 |
BusinessWeek
March 29, 2004
Kerry Capell |
A Drug Behemoth In The Making? Novartis plus Aventis would create the world's No. 2 drugmaker, unless politics get in the way   |
BusinessWeek
February 9, 2004
Kerry Cappell |
This Bid Looks Like Bad Medicine Sanofi's lowball offer for giant drugmaker Aventis is unwise for both companies |
The Motley Fool
August 31, 2005
Stephen D. Simpson |
Sanofi-Aventis: A Mix of News The company gave investors a lot of information for the second quarter, with not all of it positive. |
The Motley Fool
April 26, 2004
J. Graham |
Sanofi Finally Nabs Aventis The French drug companies make a deal to merge. |
The Motley Fool
July 28, 2010
Brian Orelli |
Fighting Hard to Keep a Blockbuster Sanofi is suing the FDA to take back approval of a competing generic drug. Did you expect something different? |
The Motley Fool
November 30, 2010
Brian Orelli |
A Witty Response to Pharma's R&D Dilemma According to GlaxoSmithKline CEO Andrew Witty, the pharmaceutical industry is a mess. That's the basic gist of his opinion piece in The Economist. |
The Motley Fool
December 21, 2010
Brian Orelli |
4 Drugmakers, 5 Deals, Christmas Is Here It looks like there were a lot of people in the business development offices at pharmaceutical companies looking to get their work done before taking off for the holidays. Check out all the deals that were announced yesterday. |
BusinessWeek
December 27, 2004
Carol Matlack |
Growing Pains At Sanofi The pipeline looks good at the world's No. 3 drugmaker -- but investors are waiting for cost cuts. |
The Motley Fool
November 26, 2010
Brian Orelli |
Black Friday Biotech Bargains Drugmakers on sale. |
The Motley Fool
May 13, 2005
Stephen D. Simpson |
Waiting for Sanofi's Next Act Sanofi-Aventis' first-quarter numbers were good. Will they soon be better? Though the stock is not the greatest idea for highly income-oriented investors, the growth-at-a-reasonable-price crowd might want to investigate further. |
The Motley Fool
September 11, 2007
Brian Lawler |
Where Momenta Stands Momenta Pharmaceuticals updates investors as to the status of drugs in its pipeline. Until the FDA makes up its mind on its lead drug, an anticoagulant, it's anyone's guess as to what the value of the pipeline is. Investors should take note. |
BusinessWeek
October 4, 2004 |
"It's a Perfect Storm" for Drugmakers Glaxo CEO Jean-Pierre Garnier answers questions about the biotech industry's hardships and how his company is improving its search for new drugs |
The Motley Fool
May 5, 2006
Stephen D. Simpson |
Sanofi-Aventis Waits It Out This is the hurry up-and-wait part of the French pharma's story, with product approvals on the way soon, investors hope. |
The Motley Fool
February 4, 2004
J. Graham |
Sanofi's Aggressive for Aventis The drug company wants larger rival Aventis any way it can get it. |
The Motley Fool
November 17, 2009
Dave Mock |
A Big Upgrade for Sanofi-Aventis This bullish call comes from more than just one analyst. |
The Motley Fool
February 14, 2008
Brian Lawler |
Sanofi Stagnates French drugmaker Sanofi-Aventis posts fourth-quarter earnings in which its top drugs get some protection, but free cash flow drops. |
The Motley Fool
January 29, 2007
Brian Lawler |
The Paris Hilton of Drug Stocks Yet another rumor about a potential merger for Bristol-Myers. Who is the winner in a Bristol-Myers and Sanofi-Aventis merger? It obviously depends on the price Sanofi is willing to pay. Investors, take note. |
The Motley Fool
November 9, 2004
Charly Travers |
Genta's on the Ropes Aventis' exit leaves the pharmaceutical company in dire straits. Genta's stock opened down 40% this morning and is now down 85% for the year. |
BusinessWeek
March 22, 2004
David Fairlamb |
Europe: Deals Are Back In Season The strong euro and healthy profits have CEOs in a mood to go shopping |
BusinessWeek
May 10, 2004
John Rossant |
The Pernicious Rise Of "Core Europe" Germany and France are building a bloc to preserve their political and economic influence. |
The Motley Fool
May 7, 2007
Brian Lawler |
Sanofi Rolls the Lawsuit Dice Investors, don't be fooled by rosy results; litigation risk still looms for the French drugmaker. |
BusinessWeek
January 12, 2004 |
Biotech: A Comeback "Balanced On A Razor's Edge" Skeptical investors want to see products that get to market and add to the bottom line. |
The Motley Fool
January 26, 2005
Rich Duprey |
Chiron's Earnings Ills Flu vaccine manufacturer expected to report significantly lower profits. |
BusinessWeek
April 12, 2004
John Rossant |
Europe Is Playing With Fire Just about everywhere you look in Europe, the protectionist rhetoric is rising. Keeping national control over key companies and industries is seen as a way to make sure jobs don't evaporate. |
The Motley Fool
October 11, 2004
Richard Gibbons |
4 Ways to Profit From Catastrophes What to do when bad news strikes a company you're watching. |
